Vistagen Therapeutics, Inc. Common Stock (VTGN) Stock Price, Quote & AI Analysis

Live VTGN stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Vistagen Therapeutics, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Vistagen Therapeutics, Inc. Common Stock (VTGN), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

VTGN
Vistagen Therapeutics, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
0.000000
High
0.000000
Low
0.000000
Volume
0
VWAP
-
Market Cap
$22,046,360.75
52W Range
$0.54 - $5.14
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Feb 11, 2026 Q3
Market
EPS Estimate: $-0.4957
Revenue Estimate: $373,320.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Vistagen Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Vistagen Therapeutics, Inc. Common Stock Overview

Company information

Company Overview

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Company Details
Market Cap
$23.08M
Shares Outstanding
39,495,500
Weighted Shares Outstanding
39,495,451
CEO
Shawn K. Singh
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Employees
59
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Vistagen Therapeutics, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...